Insights

Innovative Growth Icosagen's recent acquisition of Carterra LSA and substantial investments in new GMP manufacturing facilities demonstrate a strong focus on expanding their discovery and development capabilities, signaling opportunities to offer advanced biotech equipment, automation tools, and supporting technologies.

Expanding Service Portfolio With over 500 projects in 2023 across therapeutic antibodies, multispecifics, and ADCs, Icosagen seeks to enhance its R&D infrastructure, indicating potential collaboration areas for innovative biotech reagents, custom assays, or breakthrough cell line development solutions.

Recognition & Leadership Awarded 'Best Business' and 'Innovator of the Year', Icosagen positions itself as a key player in the European biotech landscape, offering opportunities for strategic partnerships, joint ventures, or supply agreements with cutting-edge biotechnologies.

Market Expansion Operating successfully since 1998 as a family-owned, independent CDMO, Icosagen is well-positioned to attract collaborations with international biotech firms seeking reliable, innovative contract manufacturing and research services.

Technology Integration The company's current tech stack and focus on developing novel platform technologies for mammalian cell lines indicate openness to adopting advanced digital tools, automation, and biotech software solutions to streamline their R&D and manufacturing workflows.

Icosagen Tech Stack

Icosagen uses 8 technology products and services including TrackJS, Cart Functionality, JSON-LD, and more. Explore Icosagen's tech stack below.

TrackJS

Analytics

Cart Functionality

E-commerce

JSON-LD

Javascript Frameworks

Microsoft

Miscellaneous

Google

Search Engines

Yoast SEO

Search Engines

Jetpack

Web Platform Extensions

Gravity Forms

Web Platform Extensions

Icosagen Email Formats	Example	Percentage
First.Last@icosagen.com	John.Doe@icosagen.com	50%
First.Last@icosagen.com	John.Doe@icosagen.com	50%

Icosagen Email Formats

Example

Percentage

First.Last@icosagen.com

John.Doe@icosagen.com

50%

First.Last@icosagen.com

John.Doe@icosagen.com

50%

Frequently Asked Questions

Where is Icosagen's headquarters located?

Icosagen's main headquarters is located at Eerika tee 1, Tartu, Estonia 61713, EE. The company has employees across 2 continents, including EuropeNorth America.

What is Icosagen's official website and social media links?

Icosagen's official website is icosagen.com and has social profiles on LinkedIn.

What is Icosagen's SIC code NAICS code?

Icosagen's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Icosagen have currently?

As of October 2025, Icosagen has approximately 201 employees across 2 continents, including EuropeNorth America. Key team members include Chief Scientific Officer: M. U.Chief Technology Officer: A. M.Chief Production Officer: R. K.. Explore Icosagen's employee directory with LeadIQ.

What industry does Icosagen belong to?

Icosagen operates in the Biotechnology Research industry.

What technology does Icosagen use?

Icosagen's tech stack includes TrackJSCart FunctionalityJSON-LDMicrosoftGoogleYoast SEOJetpackGravity Forms.

What is Icosagen's email format?

Icosagen's email format typically follows the pattern of First.Last@icosagen.com. Find more Icosagen email formats with LeadIQ.

When was Icosagen founded?

Icosagen was founded in 1999.

Icosagen

Biotechnology ResearchEstonia201-500 Employees

Icosagen is a unique European CRDMO, being successfully in the business for more than 25 years as an independent family-owned company. As such, we combine pre-clinical CRO and clinical CDMO development expertise at one single site for therapeutic antibodies, multispecifics, ADCs, and other complex recombinant protein drug candidates.

As a CRDMO we discover, develop, and manufacture proteins seamlessly from research concepts into pre-clinical and clinical development stages. This includes everything from small-scale transient productions to stable high producing cell lines, to manufacture clinical GMP materials in our modern 200/1000L GMP facility.

In 2024, we continued our partnership with over 100 biotech & pharma companies on 500 projects, producing more than 2000 different proteins.

Insights

Similar companies to Icosagen

Absolute Antibody

PeproTech, now part of Thermo Fisher Scientific

Creative Diagnostics

Miltenyi Biotec, Inc

Icosagen Tech Stack

Media & News

Icosagen AS received award Best Business" and "Innovator of the Year on Nov 4th '23.

Icosagen AS acquires Carterra, Inc..

Icosagen AS invests into assets: 1,600 m^2 production facility in the amount of $19M.

Icosagen AS invests into assets: facility in the amount of $42.8M.

Naturalantibody partners with Icosagen AS.

Icosagen AS launches complete CE-IVD product.

Icosagen AS is developing novel platform for mammalian cell line development.

Icosagen's Email Address Formats